Results for 'E-R analyses'

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
Nov 20th • 12 mins read

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
Sep 6th • 17 mins read

Sponsorship of oncology clinical trials in the United States according to age of eligibility
Apr 29th • 8 mins read

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
Apr 1st • 14 mins read

The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review
Jan 3rd • 10 mins read

Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
Jun 10th • 30 mins read

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
Jul 28th • 20 mins read

Defining the role of real-world data in cancer clinical research: The position of the
Mar 20th • 10 mins read

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
May 18th • 5 mins read

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016
Nov 10th • 6 mins read

Sponsorship of oncology clinical trials in the United States according to age of eligibility
Apr 29th • 6 mins read

Dose Finding in the Clinical Development of 60 US Food and Drug Administration-Approved Drugs Compared With Learning vs. Confirming Recommendations
Jun 29th • 15 mins read